ZURICH, Nov 30 (Reuters) - Roche Holding AG’s (ROG.VX: Quote, Profile, Research) richly-valued stock could take a significant hit next week if a U.S. regulatory panel advise against approving its key Avastin drug in breast cancer, analysts said.The U.S. Food and Drug Administration has delayed approval of Avastin as a first-line treatment for metastatic breast cancer but its advisory panel will review the blockbuster next Wednesday, Dec 5.
